Lundbeck’s investigational oral orexin 2 receptor agonist gains Fast Track status, aiming to address underlying pathophysiology in patients with narcolepsy.

One in about 7300 individuals in the general population have PMS, a rare genetic condition that causes medical, intellectual, and behavioral challenges.

For patients aged 4 to 66 years with acquired hypothalamic obesity, setmelanotide leads to significantly greater reductions ...

Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.

Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.

Cherry angiomas (CAs), also known as Campbell de Morgan spots, are common, benign, well-demarcated cutaneous vascular ...

Delaying JAK inhibitor initiation yielded higher early antibody responses; earlier initiation linked to earlier improvement in arthritis.

In the CALIBRATE trial, 76% of encaleret-treated patients normalized both blood and urine calcium at week 24 vs 4% on standard of care, while 91% achieved intact PTH restoration.

The FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for pretreated, advanced squamous cell carcinoma of the anal canal based on phase 1/2 GOBLET trial ...

For those ultimately able to fill the prescription, study revealed treatment was delayed by 12 days on average.

Benefits include improvements for resilience and prosocial behavior, but not symptoms of anxiety or depression.

Mean total annual payment increased from $4936 to $6722 and from $2651 to $6811 for those with and without diabetes, respectively.